The Therapeutic Role of Soluble Adenylyl Cyclase Inhibition in Ameliorating Inflammatory Vascular Remodeling in Pulmonary Arterial Hypertension
Key Takeaways
- Full and open competition - all businesses eligible to bid
- Work to be performed in BETHESDA, MD
- Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Contract Details
- Notice ID
- 75N98026R00085
- Opportunity Type
- Special Notice
- Sub-Agency
- NATIONAL INSTITUTES OF HEALTH
- Office
- NATIONAL INSTITUTE OF HEALTH NIH-OD
- Posted Date
- Monday, September 14, 2026
- Response Deadline
- Monday, September 21, 2026
- PSC Code
- AN12
- Set-Aside
- Full & Open Competition
- Place of Performance
- BETHESDA, MD, 20892
- Status
- Active
Description
The National Institutes of Health (NIH) intends to negotiate on a sole-source basis with the University of Illinois at Chicago (UIC) for preclinical animal research services to evaluate the therapeutic effects of soluble adenylyl cyclase (sAC) inhibition on pulmonary arterial hypertension (PAH) using an established endothelial cell-specific Cav1 knockout (EC-Cav1 KO) murine model and corresponding wild-type controls. The Government intends to solicit from a single source pursuant to FAR 13.106-1(b)(1). UIC currently maintains the established EC-Cav1 KO mouse colony required for this study, and the model is not known to be maintained by another laboratory. This notice of intent is not a request for competitive quotations. However, all responsible sources that believe they can satisfy the Go
Why This Opportunity Matters
HEALTH AND HUMAN SERVICES, DEPARTMENT OF is seeking responses for research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) in BETHESDA, MD.
Similar Opportunities
Browse Related
Looking for more opportunities?
Browse our full directory of government contracts
